EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise

Fei Yin iD

The FEBS Journal · 2023-03 · 290 (6) · 1420-1453

DOI: 10.1111/febs.16344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 18.01.2022. Verfasst von Fei Yin. Beteiligte Einrichtung: Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 445-mal zitiert (Crossref) und nennt 406 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is an age‐associated neurodegenerative disorder with multifactorial etiology, intersecting genetic and environmental risk factors, and a lack of disease‐modifying therapeutics. While the abnormal accumulation of lipids was described in the very first report of AD neuropathology, it was not until recent decades that lipid dyshomeostasis became a focus of AD research. Clinically, lipidomic and metabolomic studies have consistently shown alterations in the levels of various lipid classes emerging in early stages of AD brains. Mechanistically, decades of discovery research have revealed multifaceted interactions between lipid metabolism and key AD pathogenic mechanisms including amyloidogenesis, bioenergetic deficit, oxidative stress, neuroinflammation, and myelin degeneration. In the present review, converging evidence defining lipid dyshomeostasis in AD is summarized, followed by discussions on mechanisms by which lipid metabolism contributes to pathogenesis and modifies disease risk. Furthermore, lipid‐targeting therapeutic strategies, and the modification of their efficacy by disease stage, ApoE status, and metabolic and vascular profiles, are reviewed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansLipid MetabolismBrainOxidative StressEnergy Metabolism

Stichwörter der Autor:innen

alzheimer’s diseasefatty acidlipid metabolismtherapeutics

Autor:innen und Institutionen

  • Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA.
  • Department of Pharmacology, College of Medicine Tucson, University of Arizona, Tucson, AZ, USA.
  • Graduate Interdisciplinary Program in Neuroscience, University of Arizona, Tucson, AZ, USA.

ORCID-Profile: Fei Yin

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Yin, F. (2023). Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. The FEBS Journal, 290(6), 1420-1453. https://doi.org/10.1111/febs.16344

Vancouver

Yin F. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. The FEBS Journal. 2023;290(6):1420-1453. doi:10.1111/febs.16344

BibTeX
@article{Yin2023,
  author = {Yin, Fei},
  title = {Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise},
  journal = {The FEBS Journal},
  year = {2023},
  volume = {290},
  number = {6},
  pages = {1420--1453},
  doi = {10.1111/febs.16344}
}
Kostenlos starten →